MNKD Earnings Date: Nov 4, 2026 (Estimated) — MannKind Corporation
NASDAQ · Healthcare · Biotechnology
Updated
When is MNKD's next earnings date?
MannKind Corporation (MNKD) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.06 on revenue of $107.7M.
How did MNKD do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), MannKind Corporation posted EPS of -$0.01 versus the -$0.01 estimate, a miss of 200.0%. Revenue was $109.4M against a $108.1M estimate. The stock's 1-day post-earnings move was -5.1%.
How much does MNKD stock move after earnings?
MNKD beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.8% (up or down) in the day after earnings.
About MannKind Corporation
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.01 | -0.01 | -200.00% | $109.4M | ❌ Miss | -5.12% | -6.10% | -3.41% |
| 2026-05-06 | Q1 2026 | 0.01 | -0.02 | -300.00% | $90.2M | ❌ Miss | -0.28% | -9.83% | -4.49% |
| 2026-02-26 | Q4 2025 | 0.01 | 0.01 | +0.00% | $112.0M | ➖ Inline | -7.43% | -15.71% | -34.29% |
| 2025-11-05 | Q3 2025 | 0.02 | 0.07 | +250.00% | $82.1M | ✅ Beat | +10.58% | -4.20% | +4.20% |
| 2025-08-06 | Q2 2025 | 0.06 | 0.05 | -16.67% | $76.5M | ❌ Miss | -13.16% | -8.27% | +33.83% |
| 2025-02-26 | Q4 2024 | 0.03 | 0.08 | +166.67% | $76.8M | ✅ Beat | -4.39% | -5.85% | -6.76% |
| 2024-11-07 | Q3 2024 | 0.03 | 0.06 | +100.00% | $70.1M | ✅ Beat | -0.61% | -5.01% | -9.88% |
| 2024-08-07 | Q2 2024 | 0.01 | 0.05 | +400.00% | $72.4M | ✅ Beat | -4.93% | -3.80% | +14.42% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $109.4M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product Revenue | 65.4% | $71.6M | +60.2% | — | — | $44.7M | $48.3M |
| Royalty | 29.6% | $32.4M | +3.7% | $75.3M | $30.0M | $31.2M | $33.3M |
| Service | 5.0% | $5.4M | +773.3% | — | — | $621K | $537K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.